Kodu・Aktsiate loetelu・DexCom Inc

DexCom Inc

Suletud

SektorTervishoid

86.95 -0.29

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

85.87

Max

87.73

Põhinäitajad
By Trading Economics
Sissetulek	50M 249M
Müük	117M 1.3B
P/E Sektori keskmine	34.51 68.51
Aktsiakasum	0.7
Kasumimarginaal	19.039
Töötajad	11,000
EBITDA	52M 389M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+3.68% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	29. okt 2026

Turustatistika
By TradingEconomics
Turukapital	4.6B 33B
Eelmine avamishind	87.24
Eelmine sulgemishind	86.95

Uudiste sentiment

By Acuity

21%

79%

64 / 340 Pingereas Healthcare

DexCom Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. aug 2026, 19:56 UTC

Dexcom Inc. shares are lower today, pulling back after reaching a session high. The broader market benefits from a significant decline in crude oil prices.

3. aug 2026, 20:02 UTC

News

Social Media

Dexcom Inc. shares are higher following strong Q2 results and raised revenue guidance to $5.22 billion. Canaccord increased its price target to $90.

31. juuli 2026, 20:04 UTC

News

Social Media

Dexcom Inc. shares are higher following analyst upgrades and strong earnings, with second-quarter revenue of $1.31 billion exceeding expectations and guidance raised to $5.22 billion.

30. juuli 2026, 23:51 UTC

News

Social Media

Dexcom reported second-quarter revenue of $1.308 billion and adjusted EPS of $0.70, raising its fiscal year 2026 revenue guidance, with shares trading higher in after-market hours.

29. juuli 2026, 23:41 UTC

Dexcom Inc is trading higher in after-market hours, supported by overall market strength. The asset remains above its 20-day moving average.

28. juuli 2026, 20:06 UTC

News

Dexcom shares rise after UBS initiated coverage with a Buy rating. The stock is advancing since Monday's close of $73.37 amid positive sentiment in the Health Care Equipment sector.

27. juuli 2026, 19:06 UTC

News

Dexcom Inc. gains Health Canada approval for its Dexcom G7 continuous glucose monitoring system, boosting marketability and user adoption amid positive analyst sentiment.

24. juuli 2026, 15:22 UTC

Dexcom Inc's shares are higher today, driven by gains in the Health Care Equipment sub-sector. No specific company news was identified for the movement.

22. juuli 2026, 20:01 UTC

Dexcom Inc. shares are lower today, continuing a decline since Tuesday. Earlier, the stock briefly rose before pulling back.

21. juuli 2026, 19:26 UTC

Dexcom Inc is trading lower, continuing a trend of three consecutive declines. The stock reached a session low earlier today before a slight recovery.

20. juuli 2026, 19:22 UTC

Dexcom Inc shares are lower amid broader market declines and rising Treasury yields. The stock remains near the upper end of its one-month trading range.

Võrdlus sarnastega

Hinnamuutus

DexCom Inc Prognoos

Hinnasiht

By TipRanks

3.68% tõus

12 kuu keskmine prognoos

Keskmine 90.52 USD 3.68%

Kõrge 112 USD

Madal 64 USD

Põhineb 23 Wall Streeti analüütiku instrumendi DexCom Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

23 ratings

Osta

Hoia

Müü

Põhineb 23 analüütiku instrumendi DexCom Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

64 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.